<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01505634</url>
  </required_header>
  <id_info>
    <org_study_id>7655-003</org_study_id>
    <secondary_id>2011-005707-32</secondary_id>
    <nct_id>NCT01505634</nct_id>
  </id_info>
  <brief_title>Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for the Treatment of Complicated Urinary Tract Infection (cUTI) (MK-7655-003)</brief_title>
  <official_title>A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety and tolerability of adding 125
      mg or 250 mg doses of MK-7655 to imipenem/cilastatin in adults 18 years or older with
      complicated urinary tract infection (cUTI). The primary hypothesis is that the MK-7655 +
      imipenem/cilastatin treatment regimen is non-inferior to imipenem/cilastatin with respect to
      the proportion of participants with a favorable microbiological response at completion of
      intravenous (IV) study therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 16, 2012</start_date>
  <completion_date type="Actual">July 28, 2015</completion_date>
  <primary_completion_date type="Actual">July 28, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with a favorable microbiological response at completion of IV study therapy</measure>
    <time_frame>At time of last IV dose of study drug (up to postrandomization day 14)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with an elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) laboratory value that is greater than or equal to 5X the upper limit of normal (ULN)</measure>
    <time_frame>Up to 14 days following completion of all study therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with elevated AST or ALT laboratory values that are greater than or equal to 3X the ULN, as well as elevated total bilirubin greater than or equal to 2X the ULN, and alkaline phosphatase values that are less than 2X the ULN</measure>
    <time_frame>Up to 14 days following completion of all study therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with any adverse event (AE)</measure>
    <time_frame>Up to 14 days following completion of all study therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with any serious adverse event (SAE)</measure>
    <time_frame>Up to 42 days following completion of all study therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with any drug-related AE</measure>
    <time_frame>Up to 14 days following completion of all study therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with any SAE and drug-related AE</measure>
    <time_frame>Up to 42 days following completion of all study therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who discontinued IV study therapy due to an AE</measure>
    <time_frame>Up to 14 days post initiation of IV study therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who discontinued IV study therapy due to a drug-related AE</measure>
    <time_frame>Up to 14 days post initiation of IV study therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with specific AEs, system organ class (SOC) or pre-defined limit of change (PDLC) with incidence of &gt;= 4 participants in one treatment group</measure>
    <time_frame>Up to 14 days following completion of all study therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a favorable microbiological response at completion of IV study therapy who have imipenem-resistant, gram-negative cUTI infections.</measure>
    <time_frame>At time of last IV dose of study drug (up to postrandomization day 14)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a favorable microbiological response at early follow-up</measure>
    <time_frame>Up to 9 days following completion of all study IV and oral therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a favorable clinical response at completion of IV study therapy</measure>
    <time_frame>At time of last IV dose of study drug (up to postrandomization day 14)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a favorable clinical response at early follow-up</measure>
    <time_frame>Up to 9 days following completion of all study IV and oral therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a favorable clinical response at late follow-up</measure>
    <time_frame>Up to 42 days following completion of all study IV and oral therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a favorable microbiological response at late follow-up</measure>
    <time_frame>Up to 42 days following completion of all study IV and oral therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">302</enrollment>
  <condition>Urinary Tract Infections</condition>
  <condition>Pyelonephritis</condition>
  <arm_group>
    <arm_group_label>MK-7655 250 mg with imipenem/cilastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-7655 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-7655 125 mg with imipenem/cilastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-7655 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to MK-7655 with imipenem/cilastatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo to MK-7655 (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-7655 250 mg</intervention_name>
    <description>Participants randomized to receive MK-7655 250 mg will be administered a 250 mg dose of MK-7655 IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.</description>
    <arm_group_label>MK-7655 250 mg with imipenem/cilastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-7655 125 mg</intervention_name>
    <description>Participants randomized to receive MK-7655 125 mg will be administered a 125 mg dose of MK-7655 IV in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.</description>
    <arm_group_label>MK-7655 125 mg with imipenem/cilastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imipenem/cilastatin 500 mg</intervention_name>
    <description>A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.</description>
    <arm_group_label>MK-7655 250 mg with imipenem/cilastatin</arm_group_label>
    <arm_group_label>MK-7655 125 mg with imipenem/cilastatin</arm_group_label>
    <arm_group_label>Placebo to MK-7655 with imipenem/cilastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to MK-7655</intervention_name>
    <description>Participants randomized to receive imipenem/cilastatin alone will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.</description>
    <arm_group_label>Placebo to MK-7655 with imipenem/cilastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>After at least 96 hours of IV treatment, participants may be switched, at the discretion of the investigator, to 500 mg ciprofloxacin, administered orally, twice daily</description>
    <arm_group_label>MK-7655 250 mg with imipenem/cilastatin</arm_group_label>
    <arm_group_label>MK-7655 125 mg with imipenem/cilastatin</arm_group_label>
    <arm_group_label>Placebo to MK-7655 with imipenem/cilastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Clinically suspected and/or bacteriologically documented cUTI or acute

        pyelonephritis judged by the investigator to be serious (requiring hospitalization and
        treatment with IV antibiotic therapy)

        - Pyuria, determined by a midstream clean-catch (MSCC) or catheterized

        (indwelling or straight catheter) urine specimen with greater than or equal to 10 white
        blood cells (WBCs) per high-power field (hpf) on standard examination of urine sediment or
        greater than or equal to 10 WBCs/mm3 in unspun urine

        - One positive urine culture within 48 hours of enrollment

        Exclusion Criteria:

        - Complete obstruction of any portion of the urinary tract (requiring a

        permanent indwelling urinary catheter or instrumentation), a known ileal loop, or
        intractable vesico-ureteral reflux

          -  A temporary indwelling urinary catheter is in place and cannot be removed at study
             entry.

          -  Perinephric or intrarenal abscess or known or suspected prostatitis

          -  Uncomplicated UTI

          -  Any history of recent accidental trauma to the pelvis or urinary tract

          -  Any amount of effective antibiotic therapy after obtaining the urine culture for
             admission to this study and prior to the administration of the first dose of IV study
             therapy

          -  An infection which has been treated with greater than 24 hours of systemic antibiotic
             therapy known to be effective against the presumed or documented etiologic pathogen(s)
             within the 72-hour period immediately prior to consideration for entry into the study

          -  History of serious allergy, hypersensitivity (e.g., anaphylaxis), or any

        serious reaction to carbapenem antibiotics, any cephalosporins, penicillins, or other beta
        (Î²)-lactam agents

          -  History of serious allergy, hypersensitivity (e.g., anaphylaxis), or any serious
             reaction to other beta-lactam inhibitors (e.g., tazobactam, sulbactam, clavulanic
             acid)

          -  History of a seizure disorder

          -  Currently being treated with valproic acid or has received treatment with

        valproic acid in the 2 weeks prior to screening.

          -  Rapidly progressive or terminal illness unlikely to survive the approximately 6 to 8
             week study period

          -  Pregnant or expecting to conceive, breast feeding, or plans to breast feed

        during the study

        - A response to all study therapy (IV study therapy or subsequent oral

        ciprofloxacin) within the timeframe of treatment specified in this protocol is

        considered unlikely.

        - Concurrent infection that would interfere with evaluation of response to

        the study antibiotics

        - Need for concomitant systemic antimicrobial agents in addition to those

        designated in the various study treatment groups (use of vancomycin, daptomycin, or
        linezolid is allowed for certain infections)

          -  cUTI due to a confirmed fungal pathogen

          -  Currently receiving immunosuppressive therapy, including use of high-dose

        corticosteroids

          -  Prior recipient of a renal transplantation

          -  Laboratory abnormalities as specified in protocol

          -  History of any other illness that, in the opinion of the investigator, might

        confound the results of the study or pose additional risk in administering the study drug

        - Currently participating in, or has participated in, any other clinical study

        involving the administration of investigational or experimental medication (not

        licensed by regulatory agencies) at the time of presentation or during the previous 30 days
        prior to screening or is anticipated to participate in such a clinical study during the
        course of this trial

        - Estimated or actual creatinine clearance of &lt;5 mL/minute, or is currently undergoing
        hemodialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Greece</country>
    <country>Guatemala</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Sims M, Mariyanovski V, McLeroth P, Akers W, Lee YC, Brown ML, Du J, Pedley A, Kartsonis NA, Paschke A. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother. 2017 Sep 1;72(9):2616-2626. doi: 10.1093/jac/dkx139.</citation>
    <PMID>28575389</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2012</study_first_submitted>
  <study_first_submitted_qc>January 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2012</study_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Pyelonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>MK-7655</mesh_term>
    <mesh_term>Cilastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

